Three years ago Everolimus was only an idea. When this drug, similar to rapamycin showed improvement in human immunity, it was time to celebrate. It was a step closer to people trying to slow down ageing. It was believed for a long time that ageing happens because on a molecular level, the body cannot repair itself quite as good as the time goes on.However, rapamycin and drugs similar to it can be used to effectively improve people’s condition, prevent diseases and slow down the possible damage done to the cells. Mikhail Blagosklonny is one of the scientists working on using rapamycin and other similar drugs to slow down ageing and treat cancer. At the moment research shows that rapamycin can be administered to people with osteoporosis and improve the life expectancy with people with Alzheimer’s. It is a drug currently administered to transplant receivers so that their bodies wouldn’t reject the newly transplanted organ. There is not enough research at the moment to know for sure what other properties Rapamycin will unravel, but it isn’t toxic, and people have not reported allergic reactions to it.
Mikhail Blagosklonny worked as a professor of oncology at the Roswell Park Cancer Institute before his interest in the connection between cancer and research started. He has both an M.D. and PhD. Experimental medicine and cardiology were his fields of study at the First Pavlov State Medical University of St. Petersburg.His career started in New York where he worked as an associate professor of medicine. Afterwards, his career led him from Valhalla to Albany where Blagosklonny applied his knowledge and expertise as scientists at the Ordway Research Institute.He worked there till 2009 when Roswell Park invited him to come onboard. His research mainly concentrates on cancer and mechanisms of ageing as well as preventative medicine.He believes that helping people to avoid cancer from appearing might be the way forward.
Any treatment that could be administered before the cancerous cells appear and multiply would allow people to not get sick in the first place. It would not right out cure patients with advanced forms of cancer, but it would decrease risks for others. It’s possible that it would eventually lead scientists to a complete cure of this debilitating disease.Mikhail Blagosklonny also works in publishing. He’s the editor of several peer-review publications, such as Cell Cycle and Oncotarget. He gives young scientist opportunities to be published and get reviewed by esteemed professionals in the field as well as their peers.Oncotarget keeps people informed about the newest discoveries and research I the field of oncology. Since Mikhail Blagosklonny is interested in the subject of cancer himself, he enjoys working with young professionals and scientists discovering new facts about cancer and its various forms.His passion and dedication are noted by his peers, and his colleagues enjoy his company and his knowledge. Mikhail Blagosklonny has a personal approach to every new research project he takes on since people’s lives could be dramatically changed because of it.